 UTRECHT, The Netherlands and PHILADELPHIA, Jan. 23, 2023 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX , an immuno-oncology company focused on developing its proprietary GammabodyTM platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that clinical data from a Phase 12a study in patients with therapy refractory metastatic castration resistant prostate cancer will be presented at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium ASCO GU in San Francisco from February 16-18, 2023. 